Mario del Cid, MD
Retina Specialist · Ft Lauderdale, FLNPI 1407037872
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,810 of the $14,102 with a category attached, or 76.7%. Regeneron accounts for 84.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $12,215 and has fallen 97.5% since, to $306 in 2025.
Across 84 payments — averaging $167.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$12K
- Regeneron Healthcare Solutions, Inc.$788
- Genentech USA, Inc.$682
- AbbVie$217
- Coherus Oncology, Inc.$148
- Apellis Pharmaceuticals, Inc.$129
- plus $287 from 9 others
Across 5 payments — averaging $5887.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$29K
What the payments were for
- Consulting fees$10,81077%
- Travel & lodging$9146%
- Food & beverage$2,36117%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 11 | $11,853 |
| Regeneron Healthcare Solutions, Inc. | 31 | $788 |
| Genentech USA, Inc. | 20 | $682 |
| AbbVie(2 entities) | 5 | $217 |
| Coherus Oncology, Inc. | 2 | $148 |
| Apellis Pharmaceuticals, Inc. | 2 | $129 |
| Novartis | 3 | $56 |
| Astellas Pharma US Inc | 2 | $54 |
| Alimera Sciences, Inc. | 2 | $43 |
| Neurotech Pharmaceuticals, Inc. | 1 | $32 |
| Harrow Eye, LLC | 1 | $29 |
| Sandoz | 1 | $22 |
| Viiv Healthcare Company | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Alcon | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,102 in reported general payments places this provider in the 75th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 100 | $6,237 |
| Bromfenac Sodium | 40 | $5,277 |
| Ketorolac Tromethamine | 58 | $1,362 |
| Brimonidine Tartrate | 23 | $756 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 47 | $424 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $420 |
| Latanoprost | 18 | $170 |
| Diclofenac Sodium | 12 | $143 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Ft Lauderdale
- Eduardo UchiyamaFt Lauderdale$356K
- Ryan ShieldsFt Lauderdale$10K
- Barry TaneyFt Lauderdale$6K
- Darin GoldmanFt Lauderdale$6K
- Robert LalaneFt Lauderdale$5K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.